Rolf Jan Rutten
Hearing loss therapies
United States of America
Rolf Jan Rutten has over fifteen years experience in management and business development in the pharmaceutical and biotechnology industry. He held various global commercial positions with Akzo Nobel and Kreatech Biotechnology, a molecular diagnostics company, before leading the commercialisation of the IP portfolio of TNO pharma. Currently he is responsible for all activities of the European subsidiaries of Clinquest Group. He was also the co-founder of Dybly AG, a Basel-based cardiovascular company.
Private biopharmaceutical company, discovery, development and commercialization of drugs and delivery technologies, diseases affecting the ear, including hearing loss